SHILPAMED Shilpa Medicare Q3 FY26 results (Oct–Dec 2025) and concall
Shilpa Medicare delivered a strong Q3 FY26, reporting its highest ever quarterly revenue and EBITDA, driven by robust growth across API and Formulation segments. The company demonstrated significant margin expansion and improved ROCE, signaling successful monetization of past investments. Strategic progress was highlighted in CDMO, complex pipeline, and biologics, with several key projects nearing commercialization or advancing in clinical stages, despite some confidentiality constraints on specific product details.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 32.8%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 130 | 125 | 126 | 92 | 135 +4% | 166 +33% |
| EBITDA | 43 | 22 | 38 | 17 | 39 −9% | 31 +41% |
| Net profit | 30 | 16 | -6 | 21 | 31 +3% | 16 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
